Study guide
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management
Professional and Linguistic Assessments Board Part 1 PLAB 1
Track your progress as you read
Finished sections get a check mark.
1 Introduction
About the PLAB 1 Exam
2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies
1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies
3 Chapter 2: Cardiovascular Medicine & Vascular Disorders
2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease
4 Chapter 3: Respiratory Medicine
3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure
5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery
4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD
6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance
5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies
7 Chapter 6: Endocrinology & Metabolic Medicine
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease
8 Chapter 7: Neurology & Neurosciences
7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders
9 Chapter 8: Psychiatry & Mental Health
8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health
10 Chapter 9: Obstetrics, Gynaecology & Sexual Health
9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence
11 Chapter 10: Paediatrics & Child Health
10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems
12 Chapter 11: Musculoskeletal Medicine & Rheumatology
11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders
13 Chapter 12: Dermatology, ENT & Ophthalmology
12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer
14 Chapter 13: Haematology, Oncology & Palliative Care
13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral
15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology
14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship
16 Chapter 15: Medical Ethics, Law & UK Clinical Practice
15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse
17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention
16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention
18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging
17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays
6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management
Key Takeaways Explain This Topic AI
Diagnostic criteria for diabetes require either clinical symptoms of hyperglycaemia plus one abnormal test result, or two abnormal results on separate occasions: Fasting Plasma Glucose ≥ 7.0 mmol/L, Random Plasma Glucose ≥ 11.1 mmol/L, 2-hour post-OGTT ≥ 11.1 mmol/L, or HbA1c ≥ 48 mmol/mol (6.5%).
Prediabetes (impaired glucose regulation) is defined by an HbA1c of 42–47 mmol/mol (6.0–6.4%) or fasting plasma glucose of 6.1–6.9 mmol/L, warranting structured lifestyle modification and annual biochemical review.
Under NICE NG28 (February 2026), most adults with type 2 diabetes start modified-release metformin plus an SGLT-2 inhibitor; atherosclerotic CVD adds subcutaneous semaglutide, and eGFR 20–29 needs dapagliflozin or empagliflozin plus a DPP-4 inhibitor (metformin stops below eGFR 30).
Individualised HbA1c targets are 48 mmol/mol for patients managed with lifestyle or a single agent not associated with hypoglycaemia, relaxing to 53 mmol/mol when regimens include drugs that carry hypoglycaemic risk (sulfonylureas, insulin); acute hypoglycaemia (< 4.0 mmol/L) requires 15–20 g of rapid-acting oral carbohydrate for alert patients, or IV 100–200 mL 10% glucose / IM glucagon 1 mg if conscious level is impaired.
Last updated: October 2026
Diabetes Mellitus: Diagnostic Criteria & Chronic Management
Diabetes mellitus comprises a group of metabolic disorders characterised by chronic hyperglycaemia resulting from defects in insulin secretion, insulin action, or both. In UK clinical practice, accurate diagnosis and early risk stratification are essential to prevent microvascular and macrovascular complications.
Diagnostic Criteria for Diabetes Mellitus
The World Health Organization (WHO) and National Institute for Health and Care Excellence (NICE) establish diagnostic criteria based on plasma glucose concentrations and glycated haemoglobin (HbA1c). Confirmation requires either:
Symptomatic patient (polyuria, polydipsia, unexplained weight loss, lethargy, recurrent infections such as candidiasis) plus ONE abnormal laboratory result .
Asymptomatic individual with TWO abnormal laboratory results on separate occasions .
- Diagnostic Modality Normal Range Impaired Glucose Regulation (Prediabetes) Diabetes Mellitus Threshold
- Fasting Plasma Glucose (FPG) < 6.1 mmol/L 6.1 – 6.9 mmol/L (Impaired Fasting Glucose, IFG) ≥ 7.0 mmol/L
- Random Plasma Glucose (RPG) < 7.8 mmol/L N/A ≥ 11.1 mmol/L (with symptoms)
2-Hour 75g Oral Glucose Tolerance Test (OGTT) < 7.8 mmol/L 7.8 – 11.0 mmol/L (Impaired Glucose Tolerance, IGT) ≥ 11.1 mmol/L
- Glycated Haemoglobin (HbA1c) < 42 mmol/mol (< 6.0%) 42 – 47 mmol/mol (6.0 – 6.4%) ≥ 48 mmol/mol (≥ 6.5%)
- Clinical Caveats & Invalidation of HbA1c
HbA1c reflects average glycaemia over the approximate 120-day lifespan of circulating erythrocytes. In clinical scenarios where erythrocyte turnover or haemoglobin kinetics are altered, HbA1c is invalid and must not be used for diagnosis :
Haemoglobinopathies: Sickle cell trait/disease, thalassaemia major or minor.
Altered erythrocyte lifespan: Haemolytic anaemia, recent blood transfusion (past 3 months), chronic blood loss, splenomegaly, or severe untreated iron-deficiency anaemia.
End-stage renal disease / Haemodialysis: Uraemia alters red cell survival and carbamylated haemoglobin interferes with assays.
Pregnancy: Gestational diabetes or pre-existing diabetes in pregnancy (must use fasting glucose and 75g OGTT).
Rapid-onset hyperglycaemia: Suspected acute Type 1 diabetes in children or young adults, steroid-induced diabetes, and pancreatic resection/acute pancreatitis.
Note
Prediabetes Management: Individuals with an HbA1c between 42 and 47 mmol/mol (6.0–6.4%) or IFG (6.1–6.9 mmol/L) have high progression rates to established type 2 diabetes. Clinical management centres on intensive lifestyle intervention (≥5% body weight reduction, Mediterranean dietary pattern, ≥150 minutes of moderate-intensity physical activity weekly) and annual HbA1c surveillance.
Type 1 Diabetes: Pathophysiology & Management
Type 1 diabetes results from T-cell-mediated autoimmune destruction of insulin-producing beta cells in the pancreatic islets of Langerhans, culminating in absolute insulin deficiency. It characteristically presents in children, adolescents, or young adults with a rapid onset of weight loss, ketonuria, polyuria, polydipsia, and fatigue, frequently progressing to diabetic ketoacidosis (DKA).
Diagnostic Biomarkers
Autoantibodies: Anti-glutamic acid decarboxylase (anti-GAD65), anti-islet antigen 2 (anti-IA-2), and anti-zinc transporter 8 (anti-ZnT8). At least one antibody is detectable in >90% of new-onset autoimmune cases.
C-peptide: Low or undetectable fasting C-peptide (< 200 pmol/L) confirms absolute endogenous insulin deficiency.
Insulin Regimens
All patients with type 1 diabetes require lifelong exogenous insulin replacement. NICE guidelines recommend a multiple daily injection (MDI) basal-bolus regimen as the standard of care:
Basal (background) insulin: Administered once or twice daily using a long-acting insulin analogue (e.g., insulin glargine, insulin degludec, or insulin detemir) to suppress hepatic gluconeogenesis overnight and between meals.
Bolus (prandial) insulin: Rapid-acting insulin analogue (e.g., insulin aspart, insulin lispro, or insulin glulisine) injected immediately before or with meals, calculated according to carbohydrate counting and ambient capillary glucose.
Glucose Monitoring: All adults with type 1 diabetes should be offered continuous glucose monitoring (CGM) or flash glucose monitoring (e.g., FreeStyle Libre) to monitor glycaemic trends, identify asymptomatic hypoglycaemia, and optimise time in target range (3.9–10.0 mmol/L).
Type 2 Diabetes: Stepped Pharmacological Management
Type 2 diabetes arises from peripheral insulin resistance combined with progressive pancreatic beta-cell secretory failure. Clinical management follows an individualised stepped pharmacological approach that prioritises organ protection (cardiovascular and renal) alongside glycaemic optimisation.
Initial Medicines: NICE NG28 (Updated February 2026)
The February 2026 update of NICE NG28 made modified-release (MR) metformin plus an SGLT-2 inhibitor the starting combination for almost all adults with type 2 diabetes, because SGLT-2 inhibitors are recommended as much for cardiovascular and renal protection as for glucose lowering. Medicines are introduced one at a time (usually metformin first, then the SGLT-2 inhibitor once metformin is tolerated), with education about sick-day rules and the risk of diabetic ketoacidosis.
Group (NICE NG28 2026) Initial Medicines
No relevant comorbidity, heart failure, obesity, or CKD with eGFR 30 or more MR metformin and an SGLT-2 inhibitor; SGLT-2 inhibitor alone if metformin is contraindicated or not tolerated
Atherosclerotic cardiovascular disease (e.g. previous MI, stroke, peripheral arterial disease) MR metformin and an SGLT-2 inhibitor and subcutaneous semaglutide (Ozempic, up to 1 mg once weekly)
Early-onset type 2 diabetes (diagnosed before 40) MR metformin and an SGLT-2 inhibitor; consider adding a GLP-1 receptor agonist or tirzepatide
eGFR 20 to under 30 mL/min/1.73m² Dapagliflozin or empagliflozin and a DPP-4 inhibitor (metformin is not used below eGFR 30)
eGFR under 20 mL/min/1.73m² Consider a DPP-4 inhibitor; if unsuitable or ineffective, pioglitazone or insulin-based treatment
Frailty MR metformin; add an SGLT-2 inhibitor only if frailty does not put the person at risk of volume depletion or hypotension (otherwise consider a DPP-4 inhibitor)
Metformin (biguanide): activates AMP-activated protein kinase (AMPK), inhibiting hepatic gluconeogenesis and increasing peripheral glucose uptake. It does not cause hypoglycaemia or weight gain. Start at a low dose with food and titrate (MR preparations reduce gastrointestinal side effects such as diarrhoea, nausea and cramps).
Renal Monitoring & Lactic Acidosis: Metformin is excreted unchanged by the kidneys; accumulation in renal impairment raises the risk of rare but life-threatening lactic acidosis . Review and reduce the dose if eGFR falls below 45 mL/min/1.73m²; stop metformin if eGFR falls below 30 mL/min/1.73m² .
SGLT-2 inhibitors (dapagliflozin, empagliflozin, canagliflozin): reduce heart failure hospitalisation, cardiovascular events and progression of kidney disease. Warn about genital fungal infection, volume depletion and euglycaemic diabetic ketoacidosis (stop during acute illness, before surgery, and on very low-carbohydrate diets).
Further medicines when HbA1c remains above the agreed target: options include a DPP-4 inhibitor, pioglitazone, a sulfonylurea, a GLP-1 receptor agonist or tirzepatide (particularly relevant if obesity is a priority), and insulin-based treatment, chosen by comorbidity, hypoglycaemia risk, weight and the person's preferences.
Antidiabetic Drug Classes Comparison
Drug Class Examples Mechanism of Action HbA1c Reduction Effect on Weight Hypoglycaemia Risk Key Adverse Effects & Clinical Caveats
Biguanide Metformin Activates AMPK; inhibits hepatic gluconeogenesis; enhances insulin sensitivity 10–15 mmol/mol (1.0–1.5%) Weight neutral / mild loss Negligible Gastrointestinal upset, vitamin B12 deficiency. Lactic acidosis risk: review if eGFR < 45, stop if eGFR < 30 mL/min/1.73m²
SGLT2 Inhibitors Dapagliflozin, Empagliflozin, Canagliflozin Inhibits sodium-glucose co-transporter 2 in renal proximal tubule; promotes glucosuria 8–10 mmol/mol (0.7–0.9%) Weight loss (2–4 kg) Negligible Mycotic genital infections, UTIs, volume depletion, euglycaemic DKA , Fournier's gangrene. Reduced glycaemic efficacy if eGFR < 45 mL/min/1.73m²
DPP-4 Inhibitors (Gliptins) Sitagliptin, Linagliptin, Alogliptin Inhibits dipeptidyl peptidase-4; prevents degradation of endogenous incretins (GLP-1/GIP) 6–9 mmol/mol (0.6–0.8%) Weight neutral Negligible Well tolerated, nasopharyngitis. Rare risk of acute pancreatitis . Linagliptin requires no renal dose adjustment
Sulfonylureas Gliclazide, Glimepiride Closes ATP-sensitive K+ channels on beta cells, triggering depolarisation and insulin exocytosis 10–15 mmol/mol (1.0–1.5%) Weight gain (2–3 kg) High Hypoglycaemia, secondary failure over time. Caution in renal impairment and elderly; gliclazide is preferred due to hepatic metabolism
Thiazolidinediones (TZDs) Pioglitazone PPAR-γ nuclear receptor agonist; promotes adipocyte differentiation and insulin sensitivity 8–12 mmol/mol (0.8–1.0%) Weight gain (fluid/fat) Negligible Fluid retention, peripheral oedema, heart failure exacerbation, increased fracture risk in postmenopausal women. Contraindicated in heart failure (NYHA I–IV) and bladder cancer
GLP-1 Receptor Agonists Dulaglutide, Semaglutide, Liraglutide Incretin mimetic; stimulates glucose-dependent insulin release, slows gastric emptying, induces central satiety 12–18 mmol/mol (1.2–1.8%) Marked weight loss (3–6 kg) Negligible Nausea, vomiting, diarrhoea, gallbladder disease, pancreatitis. NICE NG28 (2026) offers subcutaneous semaglutide with metformin and an SGLT-2 inhibitor in atherosclerotic CVD, and considers a GLP-1 receptor agonist or tirzepatide (dual GIP/GLP-1 agonist) in early-onset type 2 diabetes
Individualised HbA1c Therapeutic Targets
NICE guidelines mandate individualised glycaemic targets to balance microvascular risk reduction against the danger of hypoglycaemia:
Patient Clinical Profile Target HbA1c (mmol/mol) Target HbA1c (%) Clinical Rationale
Lifestyle intervention alone or monotherapy not associated with hypoglycaemia (e.g., Metformin, SGLT2i, DPP-4i, Pioglitazone) 48 mmol/mol 6.5% Maximises microvascular protection without risking drug-induced hypoglycaemic episodes
Regimen incorporating a drug associated with hypoglycaemia (e.g., Sulfonylurea, Meglitinide, or Insulin) 53 mmol/mol 7.0% Provides a physiological safety margin to prevent neuroglycopenic events and falls
Escalation threshold on existing therapy: Inadequate control requiring drug intensification ≥ 58 mmol/mol ≥ 7.5% Action threshold to trigger dual or triple therapy review
Frail elderly, severe chronic kidney disease, significant cardiovascular disease, or hypoglycaemia unawareness 58 – 64 mmol/mol 7.5 – 8.0% Avoids severe hypoglycaemia, cardiovascular strain, and fall-related morbidity
Hypoglycaemia: Recognition & Emergency Management
Hypoglycaemia in adults with diabetes is defined biochemically as a blood glucose concentration < 4.0 mmol/L ("Four is the floor"). Symptoms divide into:
Autonomic (early warning): Tremor, diaphoresis, palpitations, tachycardia, anxiety, pallor, and hunger (mediated by sympathetic and cholinergic activation).
Neuroglycopenic (cerebral glucose deprivation): Inattention, confusion, behavioural changes, dysphasia, visual disturbances, seizures, coma, and focal neurological deficits. [ Capillary Glucose < 4.0 mmol/L ]
- │
- ┌──────────────────────┴──────────────────────┐
- ▼ ▼
- [ Patient Alert, Conscious & Swallowing ] [ Patient Unconscious, Aggressive or NPO ]
- │ │
- [ Step 1: Rapid Carbohydrate ] ┌──────────────┴──────────────┐
- 15-20 g fast-acting oral glucose: ▼ ▼
- 150-200 mL pure fruit juice or cola [ IV Access Present ] [ No IV Access / Community ]
- 4-5 Jelly Babies or 4-5 GlucoTabs │ │
- │ 100-200 mL 10% Glucose 1 mg Glucagon IM/SC
- [ Step 2: Recheck at 15 min ] IV over 10-15 minutes (Recovery in 10-15 min)
- │ │ │
- ┌───────────┴───────────┐ └──────────────┬──────────────┘
- ▼ ▼ │
- [ Still < 4.0 mmol/L ] [ Resolved ≥ 4.0 mmol/L ] ▼
- Repeat Step 1 (up to 3x) [ Step 3: Complex Carbohydrate ] [ Once Conscious & Safe ]
- Give long-acting carbohydrate: Give oral complex carbohydrate
- Slice of toast / 2 biscuits
- Next planned meal containing carbs
Warning
Glucagon Limitations: Intramuscular glucagon acts by mobilising hepatic glycogen reserves. It is ineffective in patients with depleted hepatic glycogen , such as those with prolonged starvation, severe liver cirrhosis, or acute alcohol-induced hypoglycaemia. In these clinical scenarios, intravenous glucose must be obtained without delay. Furthermore, hypertonic 50% intravenous glucose is no longer recommended due to the high risk of severe extravasation necrosis and chemical thrombophlebitis; 10% intravenous glucose is the standard fluid.